MIRM - Mirum Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$146.00
DETAILS
HIGH:
$185.00
LOW:
$118.00
MEDIAN:
$145.50
CONSENSUS:
$146.00
UPSIDE:
24.73%
About Mirum Pharmaceuticals, Inc. (https://www.mirumpharma.com)
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Christopher Peetz | Chief Executive Officer & Director | 1979 | $1,826,000 USD |
| Peter Radovich | Chief Operating Officer & President | 1978 | $1,159,000 USD |
| Eric H. Bjerkholt | Chief Financial Officer | 1960 | $1,002,000 USD |
| Joanne J. Quan | Chief Medical Officer | 1964 | $1,002,000 USD |
| Lara Longpre | Chief Development Officer | 1970 | $678,200 USD |
| Andrew McKibben | Senior Vice President, Strategic Finance & Investor Relations | – | – |
| Douglas T. Sheehy | Chief Legal Officer & Secretary | 1967 | – |
| Erin Campany | Chief People Officer | 1968 | – |
| Jean-Luc Girardet | Chief Technical Officer | – | – |
| Meredith Kiernan | Senior Director of Global Corporate Communications | – | – |